Quetiapine Fumarate Tablet
Product Images NDC 70518-2752

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Quetiapine Fumarate (NDC 70518-2752). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

156f500b 643d 4f44 9963 C65d2ec23f37 01

156f500b 643d 4f44 9963 C65d2ec23f37 01
Chemical structure of quetiapine fumarate showing the quetiapine moiety and the fumarate ion. The diagram illustrates the molecular arrangement including rings, nitrogen, sulfur atoms, and associated bonds.*
FDA Label Image

156f500b 643d 4f44 9963 C65d2ec23f37 02

156f500b 643d 4f44 9963 C65d2ec23f37 02
A survival curve chart showing the proportion of patients with relapse (%) over time (weeks) for two groups: QTP+LI/VAL (dashed line) and PLA+LI/VAL (solid line). The chart tracks relapse rates over 100 weeks, with the PLA+LI/VAL group showing a higher relapse proportion compared to the QTP+LI/VAL group.*
FDA Label Image

156f500b 643d 4f44 9963 C65d2ec23f37 03

156f500b 643d 4f44 9963 C65d2ec23f37 03
A line graph depicting the proportion of patients with relapse (%) over time in weeks, up to 100 weeks. The graph compares two treatment groups: one receiving quetiapine fumarate plus lithium/valproate (QTP+LI/VAL) represented by a dashed line, and the other receiving placebo plus lithium/valproate (PLA+LI/VAL) shown by a solid line. The graph shows that the PLA+LI/VAL group has a higher relapse proportion over time compared to the QTP+LI/VAL group.*
FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
Label for Quetiapine fumarate 400 mg oral tablets, quantity 30. The label includes the NDC number 70518-2752-00, manufacturer Lupin Pharma, Baltimore, MD, and repackaging information by RemedyRepack Inc. It states storage conditions and advises to see package insert for directions. The label includes a QR code and a caution to keep medication out of reach of children.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.